title: Treatment with adenosine diphosphate receptor inhibitors-longitudinal assessment of treatment patterns and events after acute coronary syndrome (TRANSLATE-ACS) study design: expanding the paradigm of longitudinal observational research.
abstract: BACKGROUND
  Platelet inhibition is critical in reducing both short- and long-term atherothrombotic risks after acute myocardial infarction (MI), especially among patients managed with percutaneous coronary intervention (PCI). Currently available antiplatelet medications, including adenosine diphosphate (ADP) receptor inhibitors, have demonstrated variability in efficacy and safety in clinical trials, yet few studies have examined contemporary "real-world" approaches to platelet inhibition and associated outcomes.
  
  
  METHODS
  TRANSLATE-ACS is a prospective observational study that will track up to 17,000 MI patients managed with PCI, from the inhospital to outpatient settings for up to 12 months postdischarge to provide a comprehensive picture of current treatment patterns and outcomes in routine clinical practice. TRANSLATE-ACS exemplifies a collaborative study design that efficiently builds upon a well-established PCI registry platform, and yet, through a systematic telephone interview follow-up process, provides important longitudinal clinical and economic follow-up capacity through 15 months after initial MI hospitalization. Furthermore, TRANSLATE-ACS incorporates a hospital-level, clustered, randomized substudy to investigate the impact of point-of-care platelet inhibition testing on subsequent patient management. Finally, TRANSLATE-ACS provides feedback through quarterly reports to participating sites on their care practices benchmarked to peer performance to support and promote longitudinal quality of cardiovascular care delivery.
  
  
  CONCLUSIONS
  TRANSLATE-ACS not only addresses important clinical and scientific questions but also includes pioneering design features that will assist in the evolution of clinical registries.
authors.affiliation: National Heart Centre Singapore, Singapore.
authors.forename: Chee Tang
authors.initials: CT
authors.lastname: Chin
authors.forename: Tracy Y
authors.initials: TY
authors.lastname: Wang
authors.forename: Kevin J
authors.initials: KJ
authors.lastname: Anstrom
authors.forename: Baojin
authors.initials: B
authors.lastname: Zhu
authors.forename: Jen-Fue
authors.initials: JF
authors.lastname: Maa
authors.forename: John C
authors.initials: JC
authors.lastname: Messenger
authors.forename: Kelley A
authors.initials: KA
authors.lastname: Ryan
authors.forename: Linda
authors.initials: L
authors.lastname: Davidson-Ray
authors.forename: Marjorie
authors.initials: M
authors.lastname: Zettler
authors.forename: Mark B
authors.initials: MB
authors.lastname: Effron
authors.forename: Daniel B
authors.initials: DB
authors.lastname: Mark
authors.forename: Eric D
authors.initials: ED
authors.lastname: Peterson
mesh_terms: D054058:Acute Coronary Syndrome / Q000188:drug therapy*; D006801:Humans; D008137:Longitudinal Studies; D018579:Patient Selection; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D058921:Purinergic P2Y Receptor Antagonists / Q000008:administration & dosage*; D016032:Randomized Controlled Trials as Topic; D012042:Registries; D012107:Research Design
chemical_list: D010975:Platelet Aggregation Inhibitors; D058921:Purinergic P2Y Receptor Antagonists